Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)

GHAPPcast

Health EN ↓ 170 episodes

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).   Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Be sure to visit the podcast's website and support the creator: ghappcast.captivate.fm

Author

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)

Category

Health

Podcast website

ghappcast.captivate.fm

Latest episode

Nov 17, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC 31.03.2026

In this episode of RhAPPcast, host Amanda Mixon, PA-C, is joined by Christina Hanson, NP, to explore the growing intersection between rheumatology and gastroenterology, focusing on shared immune pathways and the evolving role of subcutaneous biologic therapies in immune-mediated inflammatory diseases (IMIDs). The conversation highlights how advances in subcutaneous (subQ) biologics for inflammator...

FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference? 24.03.2026

Thank you to Johnson & Johnson for the support on this FAQ Video Module. In this FAQ video module, Tedra Gray, a gastroenterology nurse practitioner at Sinai Chicago, breaks down the key differences between treat-through and randomized withdrawal clinical trial designs in inflammatory bowel disease (IBD). This educational overview explains how these two study designs impact the evaluation of n...

Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data 17.03.2026

Thank you to Johnson & Johnson for the support on this Medication Review Video Module. In this medication review video module, Kimberly Orleck, PA-C, reviews the long-term efficacy and safety of guselkumab in the treatment of Crohn’s disease, highlighting results from the Phase 3 GALAXI-2, GALAXI-3, and GRAVITI clinical trials and their long-term extension (LTE) data through week 96. The discu...

Podcast: Inflammation Intersection: A Rheum-Gi Dialogue 10.03.2026

In this podcast, host Amanda Mixon, PA-C, leads a 2026 Fireside Chat exploring the intersection of rheumatology and gastroenterology. Joined by Kim Orleck, PA-C (GI APP), and Wendy Simmons, PA-C (Rheumatology APP), the panel discusses the shared inflammatory pathways linking Crohn’s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis, with a focus on the gut–joint–skin axi...

Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results 24.02.2026

Thank you to AbbVie for the support on this Journal Club Review Video Module. In this journal club review, Kimberly Orleck, PA-C, discusses the long-term efficacy and safety of risankizumab, an IL-23 p19 inhibitor, in moderate to severely active Crohn’s disease, highlighting results from the FORTIFY maintenance trial and its open-label extension. Data show strong Week 52 clinical remission and end...

Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know 17.02.2026

Thank you to AbbVie for the support on this podcast episode. In this GHAPP podcast episode, Brooke Hodnik, PA, and Jamie Brogan, APRN, discuss the October 10, 2025 FDA label update for upadacitinib in adults with moderate to severe ulcerative colitis and Crohn’s disease. They break down what the expanded indication means in practice, including how clinicians should interpret terms like “clinically...

FAQ: Biomarkers: The Non-Invasive Future of HCC Detection 12.02.2026

Thank you to Fujifilm for their support on this FAQ Video Module. In this FAQ video module, Patrick Horne, NP, President of GHAPP and nurse practitioner at the University of Florida, provides a clear, practical overview of FDA-cleared biomarkers used in the detection and risk assessment of hepatocellular carcinoma (HCC). This discussion walks through key blood-based tests including AFP-L3, des-gam...

FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications 10.02.2026

Thank you to AbbVie for their support on this FAQ Video Module. In this FAQ video module, Brooke Hodnick, PA-C, breaks down key updates to the expanded upadacitinib label for adults with moderate to severe ulcerative colitis and Crohn’s disease, effective October 10, 2025. The discussion focuses on what qualifies as an “approved systemic therapy” in the context of patients who have had an inadequa...

FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications? 03.02.2026

Thank you to AbbVie for their support on this FAQ Video Module. In this FAQ video module, Jamie Brogan, APRN from the IBD Center at Northwestern Medicine, breaks down the October 2025 FDA label expansion for upadacitinib in adult patients with moderate to severely active ulcerative colitis and Crohn’s disease. The discussion focuses on the updated indication for patients with an inadequate respons...

FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH? 27.01.2026

Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Allysa Saggese, NP, reviews how clinicians can balance systemic and liver-directed therapies in the treatment of metabolic dysfunction–associated steatohepatitis (MASH) and shares insights on the evolving role of combination therapy. The discussion explores current guideline-aligned options, including GLP-1–based...

FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH? 20.01.2026

Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Alison Moe, PA-C, discusses how alcohol consumption impacts the evaluation and progression of metabolic dysfunction–associated steatohepatitis (MASH) and why accurate assessment is critical in clinical practice. The discussion reviews the synergistic effects of alcohol and metabolic liver disease on fibrosis progr...

Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment 13.01.2026

Thank you to Madrigal for their support of this Medication Review Video Module. In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2–F3). The...

APP Roundtable: Approach To Starting Treatments in Patients With CHB 07.01.2026

In this expert-led podcast discussion on hepatitis B management, Elizabeth Goacher, PA-C, from Duke University Medical Center and Allison Moser, NP, from RUSH University Medical Center break down what’s new in chronic hepatitis B care and how evolving guidelines are shaping real-world clinical decision-making. Recorded onsite at GHAPP National, the conversation explores updated treatment threshold...

APP Roundtable: Navigating Difficult Conversations in CHB 07.01.2026

This in-depth conversation explores how advanced practice providers navigate some of the most challenging discussions in the care of patients living with chronic hepatitis B. Drawing from years of real-world hepatology and transplant experience, Jennifer Geremia, PA-C, and Andrea Keller, PA, discuss culturally sensitive communication, addressing stigma, improving health literacy, and building trus...

APP Roundtable: Addressing Co-Morbidities in CHB 06.01.2026

In this expert-led podcast discussion, Patrick Horne and HoChong Gilles explore the complex management of comorbidities in patients with chronic viral hepatitis, with a focus on hepatitis B, hepatitis C, and HIV co-infection. The conversation highlights practical strategies for treatment sequencing, preventing hepatitis B reactivation during DAA therapy, managing drug–drug interactions, and optimi...

FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History? 06.01.2026

Thank you to Madrigal for your support on this FAQ Video Module. In this short FAQ video module, Patrick Horne, President of GHAPP and a nurse practitioner at the University of Florida, discusses the critical role of noninvasive tests (NITs) in risk stratification and patient selection for patients with metabolic dysfunction–associated steatohepatitis (MASH). He explains how serum biomarkers and i...

Journal Club: Review of Focused Recommendations for the Management of MASLD 16.12.2025

Thank you to Madrigal for your support on this Journal Club Review video module. This journal club review explores the 2025 focused recommendations for the management of metabolic dysfunction–associated steatohepatitis (MASH) developed by advanced practice providers (APPs) across the United States and published in the Journal of Clinical Gastroenterology. Brian Lam, PA-C, reviews the evolving role...

Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations 09.12.2025

Thank you to Madrigal for your support of this Medication Review Video Module. Discover how Resmetirom is reshaping the treatment landscape for metabolic dysfunction–associated steatohepatitis (MASH) in this expert-led medication review with HoChong Gilles, DNP. This short medication review breaks down the therapy’s mechanism of action, pivotal MAESTRO-NASH trial data, fibrosis and steatohepatitis...

FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients? 02.12.2025

Thank you to Madrigal for your support on this FAQ Video Module. In this episode, Christina Hanson, NP, breaks down the key functional and prognostic differences between fibrosis stage F3 and F4, explaining how liver architecture, portal hypertension, and risk of decompensation shape patient outcomes. Learn how staging impacts mortality risk in MASLD/MASH, why accurate identification of advanced f...

The Conversation That Matters: Talking to Patients About Obesity and IMIDs 01.12.2025

In this final episode of our RhAPP, MAPP, GHAPP, and SDPA crosscast series, expert APPs from dermatology, gastroenterology, rheumatology, and obesity medicine break down the most important conversation of all—how to talk to patients about obesity and immune-mediated inflammatory diseases (IMIDs). This discussion focuses on real-world communication strategies, reducing stigma, motivational intervie...

From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs 24.11.2025

In this cross-specialty episode of our RhAPP, GHAPP, MAPP and SDPA collaborative series, leading APPs from dermatology, gastroenterology, rheumatology, and metabolic medicine break down real-world strategies to improve outcomes for patients living with both obesity and immune-mediated inflammatory diseases (IMIDs). Building on earlier discussions about epidemiology and pathophysiology, this conver...

GHAPPcast: Women of Childbearing Age With IBD 18.11.2025

Thank you to AbbVie for your support on this podcast episode. Navigating pregnancy with inflammatory bowel disease (IBD) can bring unique questions, concerns, and misconceptions—especially for women of childbearing age. In this expert-led episode, Janette Villalon, PA and Angelina Collins, MSN, ANP-BC, two dedicated IBD specialists break down the latest evidence and global consensus recommendation...

The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs 17.11.2025

In this episode of our crosscast series shared across RhAPPcast, GHAPPcast, and Dermcast, we explore the hidden costs of obesity in immune-mediated inflammatory diseases (IMIDs) and how excess adiposity drives poorer outcomes, reduced treatment response, and increased healthcare burden. Hosted by Amanda Mixon, PA-C, president of RhAPP, this discussion brings together expert APPs from rheumatology,...

FAQ: How Do You Explain Remission To A Patient? 13.11.2025

Thank you to AbbVie for your support on this FAQ Video Module. In this GHAPP FAQ Video Module, Christie Morrison, from Oshi Health and Texas Digestive Disease Consultants, explains how to discuss clinical remission with patients living with inflammatory bowel disease (IBD), including both Crohn’s disease and ulcerative colitis. She breaks down the different types of remission—clinical, biochemical...

GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient 11.11.2025

Thank you to AbbVie for your support on this podcast. In this episode of the GHAPP Podcast, Alison Krustapentus, NP-C and Christie Morrison, NP, join for an open discussion on mental and sexual health in inflammatory bowel disease (IBD). Together they explore the often-overlooked psychological and relational challenges that accompany chronic conditions like Crohn’s disease and ulcerative colitis—c...

Listen to the GHAPPcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.